ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Data extraction: February 2022
2
For incidence report, "all types of cancer" include new diagnoses of invasive malignant cancers in all anatomic sites and in-situ urinary bladder.
3
For mortality report, "all types of cancer" include deaths with underlying cause of death associated with all invasive malignant cancers.
4
Data sources: Rhode Island Cancer Registry (incidence) & CDC National Center for Health Statistics (mortality)
5
Analytic sotware used: SEER*Stat v8.4.0 (seer.cancer.gov/seerstat) & Jointpoint Regression Analysis v4.8.0.1 (http://surveillance.cancer.gov/jointpoint/)
6
Cancer site grouping and coding are based on the primary site and histology data submitted to the RICR. SEER Site Recode ICD-O-3/WHO 2008 Definition is avaiable at: https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html
7
Rates are per 100,000 and age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130).
8
Confidence intervals (Tiwari mod) are 95% for rates.
9
Statistic not displayed when count of cases are fewer than 6-10 (incidence) or 15 (mortality) or >30% of RSE.
10
11
Rhode Island Cancer Registry collects, process and reports primary malignant cancers of all anatomic sites (excl. basal and squamous cell carcinomas of the skin), and non-malignant cancers in the brain and CNS.
12
Non-primary, recurrent or metastatic cancers are not “reportable”, according to the Rhode Island State Regulation for the Cancer Registry.
13
For a detailed description of the reportable cancers, please review the Rhode Island State Regulation for the Cancer Registry: https://rules.sos.ri.gov/regulations/part/216-10-10-2.
14
Case count and rate reporting discrepancies between this report and other RICR publications are possible due to the delayed reporting for some cancer cases, corrections or updates from the reporting facilities, cancers diagnosed outside of the state, or cancers identified from death certificates or other sources of data.
15
16
Notes on 23-Area Subcounty Report: cancer incidence by sex and anatomic site in 23 sub-county geographic areas. Twenty-three (23) areas were created through aggregation or division of cities/towns, using census tract populations and boundaries, to generate stable and reliable cancer statistics, and protect confidentiality of data. In each 23 sub-county area, Standardized Incidence Ratio (SIR), ratio of reported and expected cancer cases, was calculated by sex and cancer site. The statewide age-specific cancer incidence rates were used as referent data, and demographic differences (age distribution) across the 23 areas were adjusted to the Rhode Island overall age distribution (19 age grouping is commonly used in the Census). The data sets display (1) actual reported cancer cases among residents of statewide and 23 sub-county geographic areas, during 5 year period (e.g. 2011-2015), (2) expected cancer cases calculated from the age-specific state cancer incidence rates, and (3) SIRs and respective 95% confidence intervals. Three different levels of cancer incidence are summarized: (1) higher numbers of cancer reporting than expected (highlighted with orange shade), (2) reported as expected (gray shade), and (3) lower numbers of cancer reporting than expected (highlighted with blue shade). An SIR of >100% indicates that a selected area's cancer incidence is higher than expected, based on estimates from the referent statewide population's cancer incidence. An SIR of 100% is interpreted as no difference between the reported cases to the expected cases. An SIR of <100% indicates that a selected area's cancer incidence is lower than expected, based on estimates from the referent statewide population's cancer incidence. Statistical significance and margin of errors (at 5% level) are assessed with 95% confidence intervals. When a 95% CI range does not include the value of 100, then it is interpreted that the number of reported cases in a selected area is significantly higher (highlighted with orange shade) or lower (highlighted with blue shade) than expected. Cancers included are invasive malignant cancers in all anatomic sites, in-situ urinary bladder, and benign/borderline tumors in the brain/CNS.
17
18
Development of this report was funded through cooperative agreement NU58DP006291 between the Rhode Island Department of Health Cancer Registry and the Centers for Disease Control and Prevention National Program of Cancer Registries.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100